Gross Sales
0
m €
European CNS market covered with own organizations
0
%
CNS Molecules
+
0
Neuraxpharm is a European leader in pharmaceuticals for disorders affecting the central nervous system (CNS). We have been specialists in this field since 1985 and our 40 years of experience bring a broad, unparalleled knowledge into our research and commercialization of CNS products.Â
Our porfolio includes more than 130 molecules and 50 brands, addressing a full spectrum of psychiatric and neurological disorders: Psychosis and Schizophrenia, Epilepsy, Multiple Sclerosis, Depression, Anxiety, Chronic and Neuropathic Pain.
Due to 40 years of specialisation, focus, knowledge and expertise in the central nervous system field, we have a strong market position in CNS in Europe.
We have a direct presence in 23 European markets and an emerging presence outside Europe through affiliates and a global distribution network
We offer strong innovative solutions and a pipeline of Value-Added medicines and novel assets to meet our CNS patients’ needs
By having proven commercial, market access and scientific expertise and capabilities, we are  the partner of choice for CNS products in Europe. At Neuraxpharm, we remain close and responsive to the expectations and needs of our key partners
An agile, high performing, and results driven team, our focus is on making a positive impact on the lives of the CNS community
A vertically integrated company from molecule to market but with an attractive asset-light business model. Our flexible structure adapts to the capabilities required for the situation
Our journey begins in 2016 with the acquisition of Spanish and German companies specialised in CNS since 1985 with an impeccable track record and recognition among healthcare professionals
An Italian company is acquired in 2017, bringing a unique expertise in nutraceuticals and consumer health products to the group, opening the way to a more direct relationship with the end consumer.
France and the United Kingdom are incorporated in 2018, as an acquired company and new affiliate respectively.
Acquisitions of CNS expert companies in Czech Republic, Slovakia, Hungary and Switzerland, and establishment of Polish and Portuguese subsidiaries.Â
Launch of the HealthTech Neuraxpharm’s Centre of Excellence to drive innovation.Â
Austria, Poland and the Republic of Ireland are incorporated as acquired companies in 2020.
Acquisition by funds advised by Permira and higher focus on innovation.
2020 also witnesses the acquisition of the market-leading prescription brand Buccolam® for Epilepsy, the only buccal midazolam approved across Europe and currently commercialised in 18 countries.
A new business unit, based in Stockholm, is established to cover the country markets of Sweden, Norway, Finland, Denmark and Iceland. Through this expansion, Neuraxpharm strengthens its position as the leading CNS specialist in Europe with a direct presence in 18 countries.
Our plan to become the European Nº1 CNS Specialist continues with our expansion into Greece through the acquisition of a CNS specialized company covering Greece and Cyprus, plus the Netherlands is incorporated with a new affiliate.
The year 2022 sees the acquisition of more than 30 established global CNS brands of Sanofi, followed by our first digital health commercialization agreement to market a wearable device to predict epileptic seizures, and ends with the licensing agreement for the European rights of Leriglitazone, an orphan drug for a rare neurological disease.Â
A new subsidiary is established in Belgium covering Belgium and Luxembourg, completing our presence in the Benelux and strengthening our footprint in Europe by reaching 98% of the European CNS market due to our direct presence in 23 countries.Â
2023 sees an emerging presence outside Europe through our first two affiliates in LATAM: Brazil and Mexico.Â
API manufacturing plant, Inke, is divested in line with our focus on CNS.
2023 concludes with an agreement with TG Therapeutics to commercialise BRIUMVI®, a treatment for relapsing multiple sclerosis (RMS), outside the US.Â
Neuraxpharm expands operations into the Middle East to cover the six members of the Gulf Cooperation Council.
We further our commitment to protecting the environment by installing >400 photovoltaic panels at our facilities in Barcelona.
In product news, Neuraxpharm launches BRIUMVI® in Germany and receives a positive recommendation for the product from NICE UK, while Buccolam®, our epilepsy treatment for children, is granted a positive opinion by the CHMP to extend the indication to include adults. The end of 2024 is marked by our strategic alliance with Pharmathen to co-develop long-acting injectable psychiatric therapies.
2023 sees an emerging presence outside Europe through our first two affiliates in LATAM: Brazil and Mexico.Â
API manufacturing plant, Inke, is divested in line with our focus on CNS.
2023 concludes with an agreement with TG Therapeutics to commercialise BRIUMVI®, a treatment for relapsing multiple sclerosis (RMS), outside the US.Â
The year 2025 begins with the acquisition of established narcolepsy treatments, Provigil® and Nuvigil®, cementing our presence in new and existing markets.
We have a direct presence in more than 23 countries in Europe, two in Latin America (Brazil and Mexico), one hub in the Middle East and access to more than 50 international countries with a global distribution and partnering network.
Our team has deep local expertise in CNS products in each of the countries in which we have our own subsidiary. In parallel, we work tirelessly to strengthen our presence worldwide through distribution or B2B agreements with other countries in EU or outside EU. At the same time, we seek to maintain and consolidate our relationships with healthcare professionals.
Barcelona (Sant Joan DespÃ), Spain
Headquarters
Production (Neuraxpharm Pharmaceuticals)
R&D Hub
Düsseldorf (Langenfeld), Germany
Headquarters
Our Executive Committee consists of experts with broad experience across pharmaceutical and related industries, with the aim to guide the organization into a successful future.
We work with partners from around the globe, sharing the benefits of our long heritage in mental health and the central nervous system together with a wide offering in CNS. We are particularly focused on developping value-added products and innovative solutions to meet the needs of our patients.
We work with an innate passion and perseverence to move health forward for our customers and patients across the globe.Â
Neuraxpharm is a vertically integrated companyÂ
We own and operate a manufacturing facility in Spain, Neuraxpharm Pharmaceuticals, specializing in solid forms and with a vertically integrated value chain from Molecule to Market.Â
This integration provides us with the flexibility to launch innovative and value-added products swiftly, responding to market demand, while ensuring the highest standards of quality and scientific robustness.Â
Neuraxpharm is vertically integrated from Molecule to Market
Internal know-how across the whole value chain enabling strong flexibility and insight
Neuraxpharm owns and operates Neuraxpharm Pharmaceuticals, a global manufacturing company based in Spain.
Our portfolio comprises of more than 120 molecules, covering different options to treat Depression, Anxiety, Parkinson’s, Alzheimer’s, Epilepsy, Schizophrenia/Psychosis and other central nervous system disorders.
With a focus on CNS, we develop and commercialize established brands, value added medicines, generics, Consumer Healthcare products, medical cannabis, beyond-the-pill solutions (digital health and medical devices) and orphan drugs. We are continuously striving to offer a wide range of effective, high quality and affordable CNS treatment options in Europe.
Join our mailing list
Get the latest updates from the Neuraxpharm.